RetinalGenix Technologies (RTGN) Cash from Operations Growth (1y) (2021 - 2026)
RetinalGenix Technologies (RTGN) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | 21.54% |
| 2 | Stryker | 127.29 Bn | 123.81 Bn | 4.50 Bn | 13.50% |
| 3 | Medtronic | 118.89 Bn | 109.67 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 73.14 Bn | 72.60 Bn | 3.85 Bn | 14.62% |
| 5 | Edwards Lifesciences | 52.06 Bn | 47.81 Bn | 1.35 Bn | 124.64% |
| 6 | Dexcom | 34.34 Bn | 32.39 Bn | 830.00 Mn | -11.16% |
| 7 | GE HealthCare Technologies | 33.79 Bn | 31.68 Bn | 2.18 Bn | 78.72% |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn | -0.23% |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | -12.60% |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | 41.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.67% |
| Dec 31, 2025 | 31.21% |
| Sep 30, 2025 | 57.95% |
| Jun 30, 2025 | 3.95% |
| Mar 31, 2025 | -14.29% |
| Dec 31, 2024 | 35.73% |
| Sep 30, 2024 | -721.23% |
| Jun 30, 2024 | -16.95% |
| Mar 31, 2024 | -111.17% |
| Dec 31, 2023 | -772.91% |
| Sep 30, 2023 | 167.42% |
| Jun 30, 2023 | -1,100.41% |
| Mar 31, 2023 | 19.85% |
| Dec 31, 2022 | 88.57% |
| Sep 30, 2022 | 72.28% |
| Jun 30, 2022 | 96.10% |
| Mar 31, 2022 | 75.76% |
| Dec 31, 2021 | 21.82% |